NASDAQ:AYLA Ayala Pharmaceuticals (AYLA) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free AYLA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.50▼$0.5050-Day Range$0.38▼$0.5852-Week Range$0.36▼$7.31VolumeN/AAverage Volume76,300 shsMarket Capitalization$7.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Ayala Pharmaceuticals alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Ayala Pharmaceuticals Stock (NASDAQ:AYLA)Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Read More Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. AYLA Stock News HeadlinesFebruary 13, 2024 | investing.comAyala Pharmaceuticals (ADXS) Earnings Dates & ReportsDecember 21, 2023 | benzinga.comAyala Pharmaceuticals Stock (OTC:ADXS) Dividends: History, Yield and DatesApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? January 19, 2023 | finanznachrichten.deAdvaxis, Inc.: Advaxis and Ayala Pharmaceuticals Complete MergerJanuary 19, 2023 | bizjournals.comCancer treatment developers Ayala Pharmaceuticals and Advaxis complete mergerNovember 17, 2022 | finance.yahoo.comAyala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual MeetingNovember 16, 2022 | finance.yahoo.comAyala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid TumorsNovember 16, 2022 | finance.yahoo.comAyala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid TumorsApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? November 4, 2022 | msn.comRecap: Ayala Pharmaceuticals Q3 EarningsNovember 4, 2022 | finance.yahoo.comAyala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 4, 2022 | finance.yahoo.comAyala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue EstimatesOctober 20, 2022 | markets.businessinsider.comAutoZone To Rise Over 9%? Plus Roth Capital Slashes PT On This Stock By 96%October 19, 2022 | msn.comWhy United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day SessionOctober 19, 2022 | baystreet.caAyala, Advaxis MergeOctober 19, 2022 | markets.businessinsider.comAyala Pharma, Advaxis Announce Merger - Quick FactsOctober 19, 2022 | bizjournals.comCancer treatment developers Ayala Pharmaceuticals and Advaxis to mergeSeptember 30, 2022 | bizjournals.comLab Notes: 4 early stage life sciences firms close financing deals; 2 drug candidates get Fast Track approvalSeptember 29, 2022 | finance.yahoo.comAyala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid TumorsSeptember 27, 2022 | finance.yahoo.comAyala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid TumorsAugust 24, 2022 | finance.yahoo.comAyala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 CongressAugust 2, 2022 | bizjournals.comPhiladelphia-area life sciences companies with the largest stock, market cap declines in first half of 2022July 27, 2022 | nasdaq.comAyala Pharmaceuticals Stock Nearly Triples on Twitter Post. Is it a Buy?July 26, 2022 | nasdaq.comAyala Pharmaceuticals Stock Nearly Triples on Desmoid Tumor Treatment NewsJuly 6, 2022 | finance.yahoo.comHC Wainwright Believes Ayala's Initial Cancer Data Is EncouragingJuly 5, 2022 | finance.yahoo.comAyala's Cancer Candidate Shrinks Tumor In Substantially All Patients In Late-Stage StudyJune 2, 2022 | finance.yahoo.comAyala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare ConferenceSee More Headlines Receive AYLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AYLA CUSIPN/A CIK1797336 Webwww.ayalapharma.com Phone857-444-0553FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,250,000.00 Net Margins-2,341.69% Pretax Margin-2,298.60% Return on Equity-182.13% Return on Assets-139.83% Debt Debt-to-Equity RatioN/A Current Ratio2.28 Quick Ratio2.28 Sales & Book Value Annual Sales$3.51 million Price / Sales2.13 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book0.21Miscellaneous Outstanding Shares14,821,000Free Float14,287,000Market Cap$7.46 million OptionableNot Optionable Beta1.98 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Roni Mamluk M.D. (Age 55)Ph.D., Pres, CEO & Director Comp: $692.06kMr. Yossi Maimon CPA (Age 51)CPA, M.B.A., MBA, CFO, Sec. & Treasurer Comp: $556.43kDr. Gary B. Gordon M.D. (Age 69)Ph.D., Chief Medical Officer Comp: $577.4kDr. Shmuel Tuvia Ph.D.Chief Scientific OfficerMs. Irit Klipper Avni M.A.VP of HRMs. Dana Gelbaum M.B.A. (Age 48)M.Sc., Chief Bus. Officer More ExecutivesKey CompetitorsSorrento TherapeuticsNASDAQ:SRNETitan PharmaceuticalsNASDAQ:TTNPCreative Medical TechnologyNASDAQ:CELZChromocell TherapeuticsNYSE:CHROGenetic TechnologiesNASDAQ:GENEView All Competitors AYLA Stock Analysis - Frequently Asked Questions How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) released its earnings results on Monday, November, 15th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.12. The firm earned $0.63 million during the quarter, compared to analyst estimates of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 182.13% and a negative net margin of 2,341.69%. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Moderna (MRNA), CrowdStrike (CRWD), Dynavax Technologies (DVAX), Block (SQ), Abbott Laboratories (ABT), Alpine Immune Sciences (ALPN), Advanced Micro Devices (AMD), BioLineRx (BLRX), Cognex (CGNX) and Micron Technology (MU). When did Ayala Pharmaceuticals IPO? Ayala Pharmaceuticals (AYLA) raised $50 million in an initial public offering on Friday, May 8th 2020. The company issued 3,300,000 shares at $14.00-$16.50 per share. Citigroup and Jefferies served as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers. This page (NASDAQ:AYLA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
